Len Lichtenfeld is deputy chief medical officer of the American Cancer Society.

Len Lichtenfeld is deputy chief medical officer of the American Cancer Society. You may obtain the full blog by clicking here.The American Cancer Society and others say CTC an effective testing and should be to by trained physicians and centers available. Others see the same data, and the conclusion of the test is not ready for prime time, require further study. Still others say we can do these studies, while the access to CTC with appropriate quality controls, but there is no money to do the studies.

But first we have Medicare help to get it done.It is my opinion and that of my colleagues here at the American Cancer Society that CTC could help reduce the disability and death from this disease. I suspect get the answers that more people to be tested for this cancer. Some of these people – especially in rural America – can not have access to colonoscopy because of the lack of trained colonoscopists in this country. Assure insure well, 60 % to 70 % of people with this new ‘virtual ‘test shielded so that a problem a problem and do not need to go on a routine colonoscopy..Multicenter input pivotal phase III clinical trial into second-line Lung Cancer Every.

About the ATTRACT – 2 phase III clinical trialATTRACT-2. is one randomized, double – blind, placebo-controlled, multicultural-center, multi – state period III study, first line approximately 900 patients who are their second processing stage IIIb / IV NSCLC are either Carcinoma and non – squamous cell histological includes. It is open for patients who previously were only be chemo and to patients bevacizumab plus bevacizumab or cetuximab as first-line treatment second line being be used prevalent in the combine second-line treatment of NSCLC..